Resources
7 Results (showing 1 - 7)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/15/2022 (updated 3/27/2024)
Pre- Pregnancy fact sheet. Information for Providers
Posted 6/2/2023 (updated 3/27/2024)
Blueprints Programs website houses a repository of evidence-based primary prevention programs and resources. You can search for programs that fit the issue you are addressing, the audience you seek to help, as well as the delivery venue.
Posted 2/19/2024 (updated 3/28/2024)
The Bureau of Justice Statistics (BJS), in the Department of Justice’s Office of Justice Programs, released Data on Maternal Health and Pregnancy Outcomes from Prisons and Jails: Results from a Feasibility Study. The study examined the availability and quality of data, the respondent burden, and the challenges of collecting data on the health and health care of pregnant women in custody at the federal, state, local and tribal levels. BJS will use the findings of this study to help determine the best strategies for implementing national data collections in correctional settings.
Posted 3/10/2024 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration's (SAMHSA) updated Overdose Prevention and Response Toolkit provides guidance to a wide range of individuals on preventing and responding to an overdose. It emphasizes harm reduction and access to treatment as essential aspects of overdose prevention.
Posted 9/1/2021 (updated 4/2/2024)
Posted 12/2/2020 (updated 4/3/2024)
Developed for the Puerto Rico Department of Health, this toolkit discusses how to screen pregnant women for substance use, screen infants for prenatal exposure to substances, recognize the signs of NAS, utilize validated screening tools, understand the importance of provider education, and engage pregnant women in the process of treatment and referral.
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.